Company Encyclopedia
View More
name
XORTX Therapeutics
XRTX.US
XORTX Therapeutics Inc., a late-stage clinical pharmaceutical company, engages in the development and commercialization of therapies to treat gout and progressive kidney disease. Its drug development programs include XRx-026, which is in the third phase for the treatment of gout; XRx-008, which is in the second phase to treat autosomal dominant polycystic kidney disease; XRx-101, which is in the second phase to treat acute kidney injury associated with respiratory virus infection; and XRX-225, which is in the preclinical stage for the treatment of type 2 diabetic nephropathy. It has a license agreement with the University of Florida Research Foundation, Inc. for the use of uric acid lowering agent to treat insulin resistance.
4.673 T
XRTX.USMarket value -Rank by Market Cap -/-

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    XORTX Therapeutics Inc. unveils investor presentation on XRx-026 for gout and kidney disease pipeline

    XORTX Therapeutics Inc. has updated its clinical and regulatory progress for XRx-026, targeting gout, highlighting successful trials and plans for a New Drug Application in 2026. The company is also advancing XRx-008 for kidney disease, with registration trials planned. The presentation details their technology, pipeline, and milestones.

    Reuters·
    US
    XRTX
    -8.17%
    Reuters·
    US
    XRTX
    -8.17%

    XORTX Therapeutics Reports Q3 2025 Financial Results

    XORTX Therapeutics Inc. reported Q3 2025 financial results, showing a decrease in total assets from $4.09M to $2.81M and an increase in liabilities. The financials reflect ongoing R&D and investor relations costs. Analysts have mixed views, with a Buy rating and C$14.00 price target, but AI analysis suggests an Underperform rating due to no revenue and consistent losses. Potential FDA advancements for gout treatment offer some hope. The company focuses on therapies for kidney disease, diabetes, and cardiovascular disease.

    Tip Ranks·
    US
    XRTX
    -8.17%
    Tip Ranks·
    US
    XRTX
    -8.17%

    XORTX Therapeutics Raises $1.1 Million in Registered Direct Offering

    XORTX Therapeutics Inc. has successfully closed a registered direct offering, raising approximately $1.1 million. The company sold 1,750,000 common shares and pre-funded warrants at $0.63 per share to an institutional investor. The offering included 572,470 common shares and 1,117,530 pre-funded warrants, with each warrant allowing the purchase of a common share at $0.001. D. Boral Capital LLC acted as the placement agent and will receive agent warrants. Proceeds will be used for working capital and general corporate purposes.

    Reuters·
    US
    XRTX
    -8.17%
    Reuters·
    US
    XRTX
    -8.17%

    XORTX Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency | XRTX Stock News

    XORTX Therapeutics Inc. has received a notification from Nasdaq regarding non-compliance with the minimum bid price requirement, as its shares have closed below $1.00 for 30 consecutive business days. The company has 180 days to regain compliance. Despite this notification, XORTX's listing on the Nasdaq Capital Market remains unaffected. The company is focused on developing therapies for progressive kidney disease and gout, with several products in clinical development.

    StockTitan·
    US
    XRTX
    -8.17%
    StockTitan·
    US
    XRTX
    -8.17%

    XORTX Therapeutics Announces US$1.1 Million Registered Direct Offering

    XORTX Therapeutics Inc. has announced a US$1.1 million registered direct offering, selling 1,746,631 common shares at US$0.63 each to an institutional investor. D. Boral Capital LLC is the sole placement agent. The net proceeds will be used for working capital and general corporate purposes, with the offering expected to close pending customary conditions and regulatory approval.

    Reuters·
    US
    XRTX
    -8.17%
    Reuters·
    US
    XRTX
    -8.17%
    © 2025 Longbridge｜Disclaimer